We are live on
!
Find out more
B
Braidwell Portfolio holdings
AUM
$3B
1-Year Est. Return
46.72%
This Fund
S&P 500
This Quarter
Est. Return
+25.03%
1 Year Est. Return
+46.72%
3 Year Est. Return
+56.07%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$3.13B
AUM Growth
-$243M
(-7.2%)
Cap. Flow
-$1.18B
Cap. Flow
% of AUM
-37.82%
Top 10 Holdings %
Top 10 Hldgs %
37.92%
Holding
93
New
20
Increased
16
Reduced
29
Closed
16
Top Buys
| 1 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$55.4M |
| 2 |
Kodiak Sciences
KOD
|
+$42.4M |
| 3 |
BrightSpring Health Services
BTSG
|
+$40.1M |
| 4 |
Celldex Therapeutics
CLDX
|
+$33.4M |
| 5 |
Illumina
ILMN
|
+$31.7M |
Top Sells
| 1 |
Xenon Pharmaceuticals
XENE
|
+$74.8M |
| 2 |
Krystal Biotech
KRYS
|
+$67M |
| 3 |
CG Oncology
CGON
|
+$58.5M |
| 4 |
Apogee Therapeutics
APGE
|
+$54.4M |
| 5 |
Danaher
DHR
|
+$42M |
Sector Composition
| 1 | Healthcare | 83.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
CAI
1
Caris Life Sciences
CAI
$4.94B
| $211M | 6.74% |
7,816,142
+500,000
| +7% | +$14.1M |
|
2
Edgewise Therapeutics
EWTX
$4.39B
| $129M | 4.14% |
5,210,831
| – | – |
|
3
Neurocrine Biosciences
NBIX
$17.3B
| $107M | 3.41% |
751,534
-128,748
| -15% | -$18.7M |
|
4
Glaukos
GKOS
$9.21B
| $104M | 3.33% |
921,979
+141,815
| +18% | +$13.5M |
|
5
Nuvalent
NUVL
$9.81B
| $82.6M | 2.64% |
821,406
-191,576
| -19% | -$18.9M |
|
|
6
Xenon Pharmaceuticals
XENE
$6.55B
| $81.8M | 2.62% |
1,825,076
-1,779,953
| -49% | -$74.8M |
|
|
7
CG Oncology
CGON
$6.44B
| $77.7M | 2.48% |
1,870,571
-1,412,746
| -43% | -$58.5M |
|
|
HNGE
8
Hinge Health
HNGE
$6.64B
| $60.6M | 1.94% |
1,304,623
+394,147
| +43% | +$19M |
|
9
Align Technology
ALGN
$13B
| $59.5M | 1.9% |
381,004
-28,687
| -7% | -$4.11M |
|
|
10
Kodiak Sciences
KOD
$2.65B
| $58M | 1.85% |
+2,072,788
| New | +$42.4M |
|
|
SLNO
11
DELISTED
Soleno Therapeutics
SLNO
| $55M | 1.76% |
1,187,859
-94,130
| -7% | -$5.16M |
|
|
CNTA
12
DELISTED
Centessa Pharmaceuticals
CNTA
| $54.7M | 1.75% |
+2,188,320
| New | +$55.4M |
|
13
NeoGenomics
NEO
$1.89B
| $54.5M | 1.74% |
4,632,801
+2,861,655
| +162% | +$30.9M |
|
14
Acadia Pharmaceuticals
ACAD
$4.44B
| $54.3M | 1.74% |
2,032,021
-346,634
| -15% | -$8.28M |
|
15
Spyre Therapeutics
SYRE
$8.86B
| $53.5M | 1.71% |
1,634,615
-943,789
| -37% | -$24.7M |
|
16
Dianthus Therapeutics
DNTH
$5.46B
| $52.5M | 1.68% |
1,273,935
+438,878
| +53% | +$17M |
|
|
17
Celldex Therapeutics
CLDX
$3.01B
| $50.5M | 1.61% |
1,858,109
+1,266,420
| +214% | +$33.4M |
|
18
Inspire Medical Systems
INSP
$1.46B
| $49.9M | 1.6% |
540,890
-342,857
| -39% | -$32.8M |
|
|
19
Krystal Biotech
KRYS
$10.3B
| $49.8M | 1.59% |
202,101
-318,300
| -61% | -$67M |
|
20
Intuitive Surgical
ISRG
$138B
| $47.2M | 1.51% |
83,417
-46,810
| -36% | -$24.9M |
|
21
Thermo Fisher Scientific
TMO
$199B
| $46.8M | 1.5% |
80,725
-33,208
| -29% | -$18.8M |
|
|
22
BrightSpring Health Services
BTSG
$13.4B
| $44.8M | 1.43% |
+1,195,786
| New | +$40.1M |
|
23
CVS Health
CVS
$135B
| $44.8M | 1.43% |
564,200
+125,600
| +29% | +$9.9M |
|
|
24
Apogee Therapeutics
APGE
$10.2B
| $43.4M | 1.39% |
575,067
-863,678
| -60% | -$54.4M |
|
25
Nurix Therapeutics
NRIX
$2.48B
| $41.4M | 1.32% |
+2,183,864
| New | +$31.4M |
|
Similar funds
NC
VVP
SP
DIG
ECP
PCM
ROTUOC
SM